相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
Maria Elena Lunati et al.
PHARMACOLOGICAL RESEARCH (2022)
Comparison of analog insulin mix 50:50 with human insulin mix 30:70 in persons with type 2 diabetes during Ramadan
Issam M. Hajjaji et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2019)
Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes
Elamin Abdelgadir et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2019)
The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes
Yanli Shao et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
W. Timothy Garvey et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS)
Mohamed Hassanein et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia
W. J. Wan Seman et al.
DIABETES OBESITY & METABOLISM (2016)
Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
Linda A. Gallo et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Multi-country retrospective observational study of the management and outcomes of patients with Type 2 diabetes during Ramadan in 2010 (CREED)
S. M. Babineaux et al.
DIABETIC MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
Janet B. McGill
DIABETES THERAPY (2014)
A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study
Mohamed Hassanein et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2014)
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
Elizabeth R. Seaquist et al.
DIABETES CARE (2013)
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial
Hans-Ulrich Haering et al.
DIABETES CARE (2013)
The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study
M. Al-Arouj et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study
Mohamed Hassanein et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study
S. R. Aravind et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial
S. Al Sifri et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Recommendations for Management of Diabetes During Ramadan
Monira Al-Arouj et al.
DIABETES CARE (2010)
Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus
Rajeev Jain et al.
PHARMACOTHERAPY (2006)
A population-based study of diabetes and its characteristics during the fasting month of Ramadan 13 countries -: Results of the Epidemiology of Diabetes and Ramadan 1422/2001 (EPIDIAR) Study
I Salti et al.
DIABETES CARE (2004)
Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting
M Mafauzy
DIABETES RESEARCH AND CLINICAL PRACTICE (2002)
分享论文
